• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Bacteremia - Pipeline Review, H2 2012 Product Image

Bacteremia - Pipeline Review, H2 2012

  • Published: November 2012
  • 47 pages
  • Global Markets Direct

Bacteremia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Bacteremia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Bacteremia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacteremia.
- A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Bacteremia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bacteremia 7
Bacteremia Therapeutics under Development by Companies 9
Bacteremia Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Bacteremia Therapeutics – Products under Development by Companies 13
Bacteremia Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Bacteremia Therapeutics Development 15
PolyMedix, Inc. 15
Trius Therapeutics, Inc. 16
Bacteremia – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
PMX-30063 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
oritavancin disphosphate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
torezolid - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
N-acetylcystein + Tigecycline + Heparin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
daptomycin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Bacteremia Therapeutics – Drug Profile Updates 31
Bacteremia Therapeutics – Discontinued Products 39
Bacteremia Therapeutics - Dormant Products 40
Bacteremia – Product Development Milestones 41
Featured News & Press Releases 41
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate Cubicin At ICAAC 2012 41
Apr 11, 2011: Trius Announces Patent Term Extension For Torezolid Phosphate 41
Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva 42
Dec 01, 2010: Cubist Receives FDA Approval For Two-Minute IV Injection Of CUBICIN 42
Jul 13, 2010: Cubist Announces Objectives Met in Phase 2 Safety Study of CUBICIN in Prosthetic Joint Infections 43
May 12, 2010: Markman Hearing in CUBICIN Patent Litigation Rescheduled to June 9, 2010 43
Dec 11, 2009: Trial Date Set for CUBICIN Patent Litigation 44
Jan 05, 2009: Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile 44
Oct 21, 2008: CUBICIN Outcomes Registry and Experience (CORE) Marks Milestone 44
Oct 16, 2008: Cubist Pharmaceuticals Q3 2008 Revenues up 41%; Net Income up 39%: Total Revenues $112.4 Million; CUBICIN Net Product Revenues $110.6 Million 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products Under Development for Bacteremia, H2 2012 7
Products under Development for Bacteremia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
PolyMedix, Inc., H2 2012 15
Trius Therapeutics, Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Bacteremia Therapeutics – Drug Profile Updates 31
Bacteremia Therapeutics – Discontinued Products 39
Bacteremia Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Bacteremia, H2 2012 7
Products under Development for Bacteremia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos